BiotechTube

AEE788 + everolimus

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain and Central Nervous System Tumors

Conditions

Brain and Central Nervous System Tumors

Trial Timeline

Oct 1, 2003 → Jun 1, 2006

NCT ID
NCT00107237

About AEE788 + everolimus

AEE788 + everolimus is a phase 1/2 stage product being developed by Novartis for Brain and Central Nervous System Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00107237. Target conditions include Brain and Central Nervous System Tumors.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT00107237Phase 1/2Completed

Competing Products

20 competing products in Brain and Central Nervous System Tumors

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Duloxetine + Sugar pillEli LillyPhase 2
52
Neurosteroid enantiomerOragenicsPhase 2
44
Patritumab deruxtecanDaiichi SankyoPhase 2
52
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Eribulin MesylateEisaiPhase 1
33
Pembrolizumab + LenvatinibEisaiPhase 2
52
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
52
GLIADELEisaiPhase 2
52
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
33
abemaciclib + abemaciclibEli LillyPhase 2
52
JNJ-17299425Johnson & JohnsonPhase 2
52
ABT-888AbbViePhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
Iressa (Gefitinib)AstraZenecaPhase 2
52
Trastuzumab deruxtecanAstraZenecaPhase 2
52
ExenatideAstraZenecaApproved
85
AZD5213AstraZenecaPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85